A Double Blind, Randomized, Cross- Over Study Examining Efficacy Of Pf-06372865 In A Photosensitivity Epilepsy Study Using Lorazepam As A Positive Control
Phase of Trial: Phase II
Latest Information Update: 18 Mar 2017
At a glance
- Drugs PF 6372865 (Primary) ; Lorazepam
- Indications Reflex epilepsy
- Focus Therapeutic Use
- Sponsors Pfizer
- 13 Mar 2017 Status changed from recruiting to completed.
- 18 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
- 21 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.